A brief review of the use and utility of growth hormone stimulation testing in the NCGS: Do we need to do provocative GH testing?

Wilson, Darrell M.; Frane, James W.

doi:10.1016/j.ghir.2005.06.005

Cited by 30 publications

(19 citation statements)

References 19 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of all the shortcomings of GH stimulation tests, which even led to a proposal that they would not be needed [158] and uncertainty among pediatric endocrinologists in the US and elsewhere about its value [159], we believe that a GH stimulation test is a necessary part of the evaluation of the short child. However, by itself the GH peak is not a strong predictor of the outcome of GH treatment [160].…”

Section: Stimulation Testsmentioning

confidence: 89%

Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation

Wit

Clayton

Rogol

et al. 2008

Growth Hormone & IGF Research

212

179

View full text Add to dashboard Cite

Section: Stimulation Testsmentioning

confidence: 89%

Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation

Wit

Clayton

Rogol

et al. 2008

Growth Hormone & IGF Research

212

179

View full text Add to dashboard Cite

“…Available evidence is derived from response to treatment in the first few years and consistently shows some predictive value of peaks <10 μg/L on gain in AH SDS [51][52][53] . However, there is no controlled, evidence-based gold standard for this cutoff, which was adopted for identifying partial cases in the continuum between complete deficiency and normal.…”

Section: Consideration and Diagnosis Of Ghdmentioning

confidence: 99%

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

DiVall²,

et al. 2016

View full text Add to dashboard Cite

Background/Aims: On behalf of the Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society, we sought to update the guidelines published in 2003 on the use of growth hormone (GH). Because idiopathic short stature (ISS) remains a controversial indication, and diagnostic challenges often blur the distinction between ISS, GH deficiency (GHD), and primary IGF-I deficiency (PIGFD), we focused on these three diagnoses, thereby adding recombinant IGF-I therapy to the GH guidelines for the first time. Methods: This guideline was developed following the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation). Results: This guideline provides recommendations for the clinical management of children and adolescents with growth failure from GHD, ISS, or PIGFD using the best available evidence. Conclusion: The taskforce suggests that the recommendations be applied in clinical practice with consideration of the evolving literature and the risks and benefits to each individual patient. In many instances, careful review highlights areas that need further research.

show abstract

“…Additionally, some have advocated for the removal of GH provocation tests from the diagnostic criteria of GH deficiency [11]. The diagnosis of GH deficiency in children continues to be a challenge with no single gold standard diagnostic method.…”

Section: Discussionmentioning

confidence: 99%

Variation in Growth Hormone Immunoassays in Clinical Practice in Canada

Amed

Delvin²,

Hamilton³

2008

Horm Res Paediatr

View full text Add to dashboard Cite

Background/Aims: The diagnosis of growth hormone (GH) deficiency in children in Canada is based on clinical, auxological, radiographic and biochemical criteria which include response to provocative GH testing. The objective of this study was to determine the variability of GH assays used at Canadian pediatric hospitals. Methods: Pooled samples of patient sera were generated at a single center and tested at 15 laboratories across Canada using local GH assays. Additional samples were analyzed using the most commonly employed assays. Results: DSL and AutoDelfia^© assays measured lower for all samples. Linear regression analysis demonstrated excellent correlation between Access 2^©, AutoDelfia, and Immulite 2000^©, however, Bland-Altman plots revealed bias when comparing these assays. Conclusions: Adequate comparison and standardization of commercially available GH immunoassays is necessary to ensure consistent interpretation of results.

show abstract

A brief review of the use and utility of growth hormone stimulation testing in the NCGS: Do we need to do provocative GH testing?

Cited by 30 publications

References 19 publications

Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation

Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

Variation in Growth Hormone Immunoassays in Clinical Practice in Canada

Contact Info

Product

Resources

About